Oncology Medical News about Busulfan

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Non-Hodgkin Lymphoma: A Single-Institution Experience
Biology of Blood and Marrow Transplantation, 09/16/09

Ulrickson M et al. – High–dose chemotherapy with autologous stem cell transplantation (ASCT) has been established as a standard form of therapy for patients with non–Hodgkin lymphoma (NHL). While many high–dose chemotherapy combinations are used, no single regimen has proved superior over another. The data indicate that in patients with NHL undergoing ASCT, Bu/Cy has efficacy and toxicity comparable to that of other reported regimens.

<< Previous
Quantifying the Survival Benefit for Allogeneic Hematopoietic...

Next >>
Effects of VEGFR-3 phosphorylation inhibitor on lymph node...

Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide
British Journal of Haematology, 10/16/09 Relevance Score: 91%

Incidence and reasons for late failure after allogeneic haematopoietic cell transplantation following BuCy2 in acute myeloid leukaemia
British Journal of Haematology, 10/16/09 Relevance Score: 80%